Bacteriological and clinical studies of cefozopran

Kaoru Okada, Yukio Kumagai, Koji Takaki, Nobuyuki Shimono, Hiroyasu Misumi, Katsuhiko Eguchi, Mika Shigematsu, Yoshiyuki Niho, Yoshiro Sawae, Kiyoshi Ninomiya

Research output: Contribution to journalArticlepeer-review


We performed bacteriological and clinical studies on Cefozopran (CZOP), a new cephalosporin antibiotic, with the following results. 1. Antimicrobial activity The MICs of CZOP against various clinical isolates were determined with an inoculum size of 106 cells/ml. MIC90 was 0.10 μg/ml against Eschemichia coli, 0.39 against Klebsiella pneumoniae, 0.78 against Enterobacter spp., 3.13 against Methicillin-resistant Staphylococcus aureus, 6.25 against Citrobacter freuindii, 12.5 against Pseudomonas aeruginosa, and 25 against Enterococcus faecalis. Its activity was more potent than control drugs ; cefuzonam, ceftazidime and cefotaxime. MIC90 of CZOP for H. influenzae was 0.39 μg/ml, but it was less active than those of the control drugs. 2. Clinical efficacy Five patients with pneumonia, including 1 with acute bronchitis, and 1 with acute tonsillitis were treated with CZOP at a daily dose of 1.0∼3.0 g for 3∼16 days. Clinical response was good in 5, fair in 1, and poor in one patient. Exanthema was seen in one patient, and elevation of GPT and eosinophilia were observed in 2, and 3 patients, respectively.

Original languageEnglish
Pages (from-to)227-232
Number of pages6
Publication statusPublished - 1993

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)
  • Infectious Diseases
  • Pharmacology
  • Drug Discovery
  • Oncology


Dive into the research topics of 'Bacteriological and clinical studies of cefozopran'. Together they form a unique fingerprint.

Cite this